XMED N Stock Overview
Xtrackers - MSCI Europe UCITS ETF is an exchange traded fund launched by Deutsche Asset & Wealth Management Investment S.A.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Xtrackers - MSCI Europe UCITS ETF Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£1,550.06 |
52 Week High | UK£1,603.63 |
52 Week Low | UK£1,418.35 |
Beta | 0 |
1 Month Change | -3.34% |
3 Month Change | n/a |
1 Year Change | -1.41% |
3 Year Change | -7.09% |
5 Year Change | 19.85% |
Change since IPO | 14.53% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
XMED N | MX Capital Markets | MX Market | |
---|---|---|---|
7D | 0% | -0.4% | 2.4% |
1Y | -1.4% | 0.7% | 2.6% |
Return vs Industry: XMED N underperformed the MX Capital Markets industry which returned 0.7% over the past year.
Return vs Market: XMED N underperformed the MX Market which returned 2.6% over the past year.
Price Volatility
XMED N volatility | |
---|---|
XMED N Average Weekly Movement | n/a |
Capital Markets Industry Average Movement | 4.0% |
Market Average Movement | 3.8% |
10% most volatile stocks in MX Market | 6.1% |
10% least volatile stocks in MX Market | 1.9% |
Stable Share Price: XMED N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine XMED N's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | n/a | n/a | n/a |
Xtrackers - MSCI Europe UCITS ETF is an exchange traded fund launched by Deutsche Asset & Wealth Management Investment S.A. The fund is managed by State Street Global Advisors Limited. It invests in the public equity markets of developed countries in Europe.
Xtrackers - MSCI Europe UCITS ETF Fundamentals Summary
XMED N fundamental statistics | |
---|---|
Market cap | Mex$73.16b |
Earnings (TTM) | Mex$0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs XMED N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
XMED N income statement (TTM) | |
---|---|
Revenue | Mex$0 |
Cost of Revenue | Mex$0 |
Gross Profit | Mex$0 |
Other Expenses | Mex$0 |
Earnings | Mex$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did XMED N perform over the long term?
See historical performance and comparison